Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday.
The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aimmune Therapeutics would command a fully diluted market value of $625 million.
Aimmune Therapeutics, which was founded in 2011, plans to list on the Nasdaq under the symbol AIMT. BofA Merrill Lynch, Credit Suisse and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of August 3, 2015.
